Skip main navigation

Home > Search Results

Main contents starts here

Search Results

81 - 100 of about 133

Total 133 documents found.

  •  
  • Licensing Proposal
  • Any information on possible candidates for in-licensing can be submitted here.
  • R&D Organizations
  • With its R&D bases located around the globe, Takeda strives toward better health for individuals and progress in medicine by developing superior pharmaceutical products.
  • Research Alliances
  • While continuing to improve its own R&D capabilities, Takeda actively pursues alliances with other pharmaceutical manufacturers, biotechnology companies, universities, and other research institutions to efficiently introduce key technologies.
  • Patients, people with disability, disaster victims etc
  • Takeda also supports patients, people with various types of disability, disaster victims, and sports and culture as the area concerning "the aim to live an affluent life with body and mind in good health," as well as "eliminating" any obstacles to such a goal.
  • Local Community
  • Through its local community activities, Takeda has multiple initiatives to contribute toward developing a bright and dream-inspiring future.
  • Date Summary 1-Oct-09 Application Submitted for Additional Indications for Helicobacter pylori Eradication by Concomitant Therapy with Proton Pump Inhibitors 1-Oct-09 Takeda to Establish Four Sales and Marketing Subsidiaries to Expand its Operations in Mexico, Turkey and Five Other Countries in Europe 19-Oct-09 Approval of an Additional Indication of BASEN ; Prevention of Onset of Type 2 Diabetes in Patients with Impaired Glucose Tolerance 2-Nov-09 Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity 18-Nov-09 TAK-438 Enters Phase 2 Clinical Trials for the Treatment of Reflux Esophagitis 25-Nov-09 Takeda Submitted an Application for an Additional Indication for Takepron Capsules 15 and Takepron OD Tablet 15 in Japan for new indications regarding Prevention of NSAIDs-Associated Gastric Ulcer/Duodenal Ulcer 2-Dec-09 Takeda to Continue Strategic Expansion with Operations in Brazil 14-Dec-09 TAK-085 Entered into Phase 3 Clinical Programs for Treat
  • 2010 2012 Mid R Pl2010-2012 Mid-Range Plan May 12, 2010 - Transformation for a New Takeda - Yasuchika Hasegawa President & CEO Takeda Pharmaceutical Company Limited Agenda 1 Outcome of 2006-2010 Mid-Range Plan 2 2010-2012 Mid-Range Plan 3 Forecasts for Financial Results 4 Strategic Investments and Returns to Shareholders 2 Operational targets in FY2010 and Results as of End of FY2009 Outcome of 2006-2010 Mid-Range Plan Achievements to date on 2006-2010 Mid-Range Plan Enhancement of R&D pipeline, toward sales of in-house ethical products of 2 trillion yen in FY2015 Not achieved Sales of in-house ethical products: 1.4 trillion yen Not achieved (1.2 trillion yen) Market share*: 2.5% 2.5% (Forecast) *Weighted average of countries where Takeda has its own sales channels R&D expenses: investment up to 20% of the sales of ethical products 22.1% EPS*: CAGR of more than 7% 7.8% (FY2006-FY2009) *Excluding extraordinary income/loss and other extraordinary factors ROE : Maintenance of 14 15% level 14 4% 3 Returns to Sha
  • SUMMARY OF FINANCIAL STATEMENTS (Consolidated) Financial Results for the First Three Quarters (April 1 to December 31, 2009) of the Fiscal Year Ending March 31, 2010 February 3, 2010 Takeda Pharmaceutical Company Limited Listed exchanges: Osaka, Tokyo, Nagoya, Fukuoka, Sapporo TSE Code: 4502 URL: Representative: http://www.takeda.co.jp Yasuchika Hasegawa, President Contact: Hiroshi Ohtsuki Corporate Officer, General Manager of Corporate Communications Department Telephone: +81 3 3278-2037 Scheduled date of securities report submission: February 15, 2010 Scheduled date of dividend payment commencement: 1. Consolidated Financial Results (April 1 to December 31, 2009) for the Fiscal Year Ending March 31, 2010 (Millions of yen, rounded to the nearest million) (1) Consolidated Operating Results (aggregated) (Percentage figures represent changes from the same period of the previous year.) Net sales Operating income Ordinary income Net income ( million) change (%) ( million) change (%) ( million) change (%) ( milli
  • Takeda Pharmaceutical Company Limited (4502) Consolidated Financial Statements for Fiscal 2009 - 4 - [Qualitative Information and Financial Statements] 1. Results of Operations (1) Analysis of Operation Results 1) Introduction Whole of the pharmaceutical industry has tendency to face a number of challenges, such as stagnation in creating breakthrough novel drugs due to the difficulties of translating new innovations to products in the marketplace, and increasingly strict criteria for the approval of new drugs in advanced countries. Drastic changes in the healthcare systems are underway in many countries, by which it is anticipated that the pharmaceutical industry will be considerably affected. First of all, in the U.S., a bill of healthcare reform which aims to increase the ratio of the insured population was passed. Under the bill, pharmaceutical companies are requested to bear the burden of some portion of funds in order to finance the expansion of available health insurance by increase of the number of po
  • Takeda Pharmaceutical Company Limited (4502) Consolidated Financial Statements for Fiscal 2009 - 18 - 3. Management Policy (1) Basic Management Policy Takeda places "Takeda-ism" (which refers to integrity, in other words, fairness, honesty, and perseverance) at the heart of all its business activities. As a research driven pharmaceutical company, Takeda aims to realize its Mission of "striving towards better health for patients worldwide through leading innovation in medicine." Takeda will achieve this by continuously creating new drugs and maximizing the potential of those products in the global market. Under its "2006-2010 Mid-Range Plan", Takeda is working to become a world-class pharmaceutical company. Takeda had made progress toward this goal including strengthening its oncology pipelines, establishing its overseas business base and enhancing its global governance structure. However, the business environment for the pharmaceutical industry is changing dramatically and some pipelines have experienced hal
  • Annual Report 2009 Based on Takeda-ism Relationship with Our Stakeholders CSR Data Book Annual Report 2009 1 CSR Data Book 2 12 14 16 18 20 22 24 26 Relationship with Society Relationship with Environment Relationship with Suppliers Relationship with Employees 8 Quality Assurance System 56 Stakeholders' Voices Employees Who Embody the Takeda-ism Ideals 28 30 32 33 34 36 37 38 40 42 43 44 46 48 50 52 54 4 Scope of Reporting Participating in the United Nations Global Compact Annual Report 2009 - Takeda Pharmaceutical Company Limited Table of Contents Editorial Policy Basic Policy on CSR / CSR Promotion Framework / CSR Activities in Fiscal 2009 Feature Feature: Access to Healthcare in Asia (Activities in Asia) Takeda's Corporate Citizenship Activities Activities in the U.S. Activities in France and Germany Activities in Italy and the UK Activities in Japan and Taiwan Activities in the Philippines and Thailand Other Activities Feature: Supply Chain Management Basic Purchasing Policy / Green Procurement and CSR P
  • The Takeda-Plan Healthcare Access Program Activities in Japan and Asia The Plan Japan, which assists children in developing countries, is a member of Plan International, a global NGO registered by the United Nations that is active in 65 countries throughout the world. In August 2009, Takeda partnered with Plan Japan to start the Takeda-Plan Healthcare Access Program. Improving the health of children in developing countries requires measures that match the differing needs of each region. There are often significant differences from country to country concerning needs involving public hygiene, nutrition, healthcare services and disease prevention. The Takeda-Plan program will operate in China, Indonesia, the Philippines and Thailand. The aim is to conduct extensive activities for giving children better access to healthcare. All four individual projects to take place as part of the Takeda-Plan program will help contribute to achieving the Millennium Development Goals* that were established by the United Nations
  • 34 Intellectual property activities are vital to our ability to contribute to society as a provider of outstanding pharmaceutical products The Four Central Themes of Intellectual Property Activities Well over 10 years is needed for the R&D process that extends from drug discovery to final approval of a new pharmaceutical product. Furthermore, despite the enormous expenditures required to develop drugs, only a very small percentage of compounds reach the market. Drugs that are approved for sale in most cases are protected by a substance patent, which covers the drug's active ingredient. This patent is critical to the R&D process. Prospects for obtaining a patent can even be the deciding factor in whether or not to proceed with the development of a product. This is why all pharmaceutical companies place so much importance on the effective use of intellectual property, including basic patents. Without sufficient intellectual property, companies would be unable to generate the earnings needed for drug developmen
  • 42 Japanese Market The Wakayama Representative Office (clockwise from left): Yuuichi Ohmoto, Tomotaka Sakurai, Keita Nakajima (Manager), Megumi Tanaka, Nobukazu Takamori, Kazuhiro Hosono, Hirokazu Nakamoto A more powerful platform for global marketing enhancing Takeda's stature in Japan, the U.S., Europe and Asia Takeda positions Japan, its home country, as a primary source of growth for the entire group. However, market conditions in Japan are challenging: to bring down health care expenses, the Japanese government is promoting generic drugs and expanding DPC (Diagnosis Procedure Combination). Within this context, our goal is to retain our leading market position, and we intend to do this by reinforcing our commitment to operating from the perspective of health care professionals and, above all, patients. Japan's No. 1 Drug Company Again in Fiscal 2008 Takeda's ethical drug sales in Japan increased 3.6 percent to 549.0 billion in fiscal 2008. In addition to leadership overall, we ranked first in drug sales
  • 18 Stakeholder's Voice Working to contribute to society as a responsible corporate citizen in the local community CSR Activity in France For the past six years, Laboratoires Takeda (LT) and the French Association of Friedreich's Ataxia (AFAF) have been collaborating to promote diagnosis of Friedreich's ataxia and distribution of information to patients and health professionals. Friedreich's ataxia is a rare genetic neurological disease characterized by difficulties in coordinating movements associated with neurological signs. It is a progressive disease, rendering sufferers unable to walk unaided within 10 to 20 years of its onset. The rarity of the disease means there is often a lack of awareness and comprehension among patients and their loved ones. In 2007, the fourth year of collaboration between AFAF and LT, LT began a volunteer assistance program. Over two days, several volunteer employees wearing orange tee-shirts looked after patients and families by helping patients to eat, move and enjoy intense hu
  • Takeda to Create Global Centers of Excellence
    Reorganization helps Takeda realize globalization vision March 31, 2009
  • Osaka, Japan, March 31, 2009 -Takeda Pharmaceutical Company Limited ("Takeda") today announced a reorganization of its corporate structure, as part of its 2006-2010 Medium-Term Plan vision to become a global pharmaceutical company with highly integrated global operations. In order to become more responsive to rapid changes in the global operating environment and to maximize the global market potential of new products and the company’s global presence, the company is streamlining executive reporting relationships to Yasuchika Hasegawa, President, by creating corporate-level, center of excellence R&D, commercial and administrative functions. Effective April 1, 2009, Shigenori Ohkawa, Ph.D., will become Chief Scientific Officer (CSO), and Alan MacKenzie will become Executive Vice President (EVP) International Operations. Additionally, a Chief Administrative Officer (CAO) role will be established.

Pages:[1] [2] [3] [4] [5] [6] [7]   Next

Page Top